BUY Alert: ER Hospitals Desperate to Buy This Drug to Save Zombie Patients
Thanks to an exciting new “ER” drug, Angioedema of doom, my name for Hereditary AngioEdema, is not a death sentence. Because of it’s life saving abilities, the demand for this drug in the United States is going to double, triple, in the next few years… and we are going to ride this drug for gains of at least 40% over the next 9 months, as a start.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Profit Alert
The FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.